The U.S. House Select Committee on the Chinese Communist Party is investigating Eli Lilly’s clinical trial activities in China. This bipartisan probe focuses on trials conducted at military-affiliated hospitals and within the Xinjiang region. Lawmakers are examining potential national security risks, ethical concerns, and human rights abuses. The committee is seeking specific information regarding data security and intellectual property protection. While no illegal activity has been identified, the inquiry signals escalating scrutiny of U.S. pharmaceutical ties to China.
Eli Lilly is transferring sole commercialization rights for its breast cancer drug, Verzenios, in mainland China to Innovent Biologics. Innovent will manage all marketing and distribution for the treatment. Lilly will maintain responsibility for the drug's manufacturing and ongoing development. This strategic shift aims to utilize Innovent’s local commercial infrastructure to increase patient access across the region.